Qingdao Vland Biotech INC. (603739.SH) has obtained a new animal drug registration certificate.

Qingdao Vland Biotech INC. (603739.SH) announced that, in accordance with the relevant regulations of the "Regulations on Veterinary Drugs Management" and the "Measures for the Registration of Veterinary Drugs", after examination by the Ministry of Agriculture and Rural Affairs, the company and its wholly-owned subsidiaries Qingdao Animal Protection National Engineering Technology Research Center Co., Ltd., Qingdao Blue Animal Health Group Co., Ltd., and other units jointly applied for the registration of "Newcastle Disease Vaccine, Avian Influenza (H9 Subtype), Avian Adenovirus Disease (Group I, Type 4), Infectious Bursal Disease Quadrivalent Inactivated Vaccine (LaSota Strain + TA Strain + LC Strain + VP2 Protein)" as three new veterinary drugs, and recently issued the "New Veterinary Drug Registration Certificate" (Ministry of Agriculture and Rural Affairs Announcement No. 987). The acquisition of the new veterinary drug certificate is the result of the company's continued emphasis on technological innovation and increased research and development investment, further demonstrating the company's innovation capabilities, enriching the company's product categories, and also a result of the company's active promotion of technology commercialization. It is expected to bring new performance growth points to the company's business.